Hisamitsu Pharmaceutical Co., Inc. (TYO:4530)

TYO:4530 Ratios and Metrics

Market cap in millions JPY. Fiscal year is March - February.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 11, 2025	Feb 28, 2025	Feb 29, 2024	Feb 28, 2023	Feb 28, 2022	Feb 28, 2021
Market Capitalization	292,867	308,076	293,429	303,688	296,969	542,719
Market Cap Growth	-5.47%	4.99%	-3.38%	2.26%	-45.28%	37.96%
Enterprise Value	185,034	196,769	173,093	157,504	157,000	411,562
Last Close Price	4181.00	4163.94	3738.10	3615.63	3384.30	6011.37
PE Ratio	15.47	14.16	21.01	25.86	30.75	58.67
Forward PE	15.95	16.20	18.33	23.68	27.63	53.21
PS Ratio	1.88	1.98	2.07	2.37	2.47	4.74
PB Ratio	1.09	1.10	1.10	1.18	1.17	2.14
P/TBV Ratio	1.13	1.14	1.14	1.19	1.18	2.16
P/FCF Ratio	34.17	59.96	55.74	62.38	19.05	278.60
P/OCF Ratio	17.69	16.42	16.13	23.86	15.47	102.61
EV/Sales Ratio	1.19	1.26	1.22	1.23	1.31	3.59
EV/EBITDA Ratio	7.27	7.80	9.44	9.52	11.50	27.90
EV/EBIT Ratio	9.95	10.41	13.15	13.58	16.82	38.57
EV/FCF Ratio	21.59	38.30	32.88	32.35	10.07	211.27
Debt / Equity Ratio	0.01	0.01	0.01	0.01	0.01	0.01
Debt / EBITDA Ratio	0.10	0.15	0.11	0.14	0.18	0.11
Debt / FCF Ratio	0.28	0.75	0.40	0.47	0.16	0.82
Asset Turnover	0.45	0.46	0.44	0.42	0.40	0.38
Inventory Turnover	2.62	2.98	3.13	3.15	2.87	2.67
Quick Ratio	3.21	3.73	3.66	4.15	5.61	5.83
Current Ratio	3.87	4.32	4.22	4.68	6.22	6.59
Return on Equity (ROE)	7.39%	8.16%	5.49%	4.72%	3.88%	3.74%
Return on Assets (ROA)	3.28%	3.52%	2.56%	2.35%	1.94%	2.20%
Return on Capital (ROIC)	4.11%	4.28%	3.11%	2.80%	2.28%	2.63%
Return on Capital Employed (ROCE)	6.30%	6.40%	4.70%	4.30%	3.40%	4.00%
Earnings Yield	6.72%	7.06%	4.76%	3.87%	3.25%	1.70%
FCF Yield	2.93%	1.67%	1.79%	1.60%	5.25%	0.36%
Dividend Yield	2.15%	2.07%	2.27%	2.32%	2.48%	1.39%
Payout Ratio	33.57%	29.96%	47.09%	57.22%	70.81%	73.58%
Buyback Yield / Dilution	3.19%	4.27%	3.03%	2.29%	0.63%	0.56%
Total Shareholder Return	5.36%	6.33%	5.30%	4.62%	3.11%	1.95%

Updated Aug 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.